Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
Status:
Completed
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
Traditionally amantadine is used at the beginning of Parkinson Disease (PD) treatment in the
early stages of the disease, as a modest antiparkinsonian symptomatic treatment. This
treatment is usually maintained for no more than the first few months of management, before
resorting to drugs deemed more effective as dopamine agonists and lévo-DOPA (L-DOPA). A more
modern use of the drug is at a more advanced stage of PD when dyskinesia are already
established and become disabling for the patients. There is no data between these two
extremes of life stages of Parkinsonism. However, the mechanisms of action of amantadine and
the pathophysiology of the motor complications induced by L-DOPA, in particular dyskinesia
suggest that the early and prolonged use of amantadine in the early years of management,
before L-DOPA-induced dyskinesia have already emerged, should have a positive impact on
long-term occurrence and fate of these symptoms, possibly through a glutamatergic mechanism
of brain plasticity-of the "disease modification" type.